These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11972505)

  • 21. [Low-molecular-weight heparin-induced bullous haemorrhagic dermatosis associated with cell-mediated hypersensitivity].
    Thuillier D; Chaby G; Dadban A; Dascotte E; Miquel-Christophe O; Andrejak M; Chatelain D; Lok C
    Ann Dermatol Venereol; 2009 Oct; 136(10):705-8. PubMed ID: 19801254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Thrombocytosis in patients treated with low-molecular-weight heparin: more common than imagined?].
    Wautrecht JC
    J Mal Vasc; 2011 Feb; 36(1):1-2. PubMed ID: 21146338
    [No Abstract]   [Full Text] [Related]  

  • 23. Tinzaparin, a low molecular weight heparin for treatment of deep vein thrombosis.
    Med Lett Drugs Ther; 2001 Feb; 43(1098):14-5. PubMed ID: 11182804
    [No Abstract]   [Full Text] [Related]  

  • 24. Low-molecular-weight heparin and calcium heparin in thrombosis prophylaxis in patients with percutaneous arterial and venous ports for colorectal liver metastases.
    Zanon C; Bortolini M; Chiappino I
    Tumori; 2005; 91(6):477-80. PubMed ID: 16457145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skin delayed-type hypersensitivity to josamycin.
    Freymond N; Catelain A; Cousin F; Nicolas JF
    Allergy; 2003 Dec; 58(12):1319-20. PubMed ID: 14616115
    [No Abstract]   [Full Text] [Related]  

  • 26. Heparin-induced skin reaction with low molecular-weight heparin.
    Manoharan A
    Eur J Haematol; 1992 Apr; 48(4):234. PubMed ID: 1317299
    [No Abstract]   [Full Text] [Related]  

  • 27. The influence of heparin's molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al., Br J Dermatol 2007; 157:514-17.
    Ludwig RJ; Schindewolf M; Lindhoff-Last E; Boehncke WH
    Br J Dermatol; 2008 Apr; 158(4):849-51. PubMed ID: 18205866
    [No Abstract]   [Full Text] [Related]  

  • 28. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study.
    Gaigl Z; Pfeuffer P; Raith P; Bröcker EB; Trautmann A
    Br J Haematol; 2005 Feb; 128(3):389-92. PubMed ID: 15667543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unfractionated- versus low-molecular-weight-heparin-associated HIT in hospitalized medical patients.
    Fraser GL; Riker RR
    J Hosp Med; 2006 Nov; 1(6):380-1; author reply 381-2. PubMed ID: 17219533
    [No Abstract]   [Full Text] [Related]  

  • 30. Update on low molecular weight heparins at the beginning of third millennium. Focus on reviparin.
    Del Bono R; Martini G; Volpi R
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):950-9. PubMed ID: 21845806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
    Whang PG; Lieberman JR
    Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Summaries for patients. Low-molecular-weight heparin given for several weeks after hip surgery prevents deep venous thrombosis.
    Ann Intern Med; 2001 Nov; 135(10):S-55. PubMed ID: 11757493
    [No Abstract]   [Full Text] [Related]  

  • 33. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids.
    Gerhardt A; Zotz RB; Stockschlaeder M; Scharf RE
    Thromb Haemost; 2007 Mar; 97(3):496-7. PubMed ID: 17334521
    [No Abstract]   [Full Text] [Related]  

  • 34. [Venous thromboprophylaxis postcaesarean: survey of practices in Lorraine].
    Vial F; Hein F; Boileau S; Vedel M; Bouaziz H
    Ann Fr Anesth Reanim; 2009 Apr; 28(4):395-6. PubMed ID: 19303734
    [No Abstract]   [Full Text] [Related]  

  • 35. Delayed hypersensitivity reaction to heparin in a pregnant woman.
    Sanders MN; Bernhisel-Broadbent J; Staker LV
    Int J Dermatol; 1995 Jun; 34(6):443-4. PubMed ID: 7657449
    [No Abstract]   [Full Text] [Related]  

  • 36. Adverse skin reactions to low molecular weight heparins: frequency, management and prevention.
    Wütschert R; Piletta P; Bounameaux H
    Drug Saf; 1999 Jun; 20(6):515-25. PubMed ID: 10392668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Leukocytoclastic vasculitis after injection of low-molecular-weight heparin (letter)].
    de Bats B; Rivard L; Bellemin B; Duflo F; Allaouchiche B; Chassard D
    Presse Med; 2000 Oct; 29(29):1604. PubMed ID: 11072362
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful Capecitabine Desensitization for a Delayed-Type Hypersensitivity Reaction.
    Demir S; Olgac M; Saglam S; Gelincik A; Colakoglu B; Buyukozturk S
    J Investig Allergol Clin Immunol; 2016; 26(1):66-7. PubMed ID: 27012024
    [No Abstract]   [Full Text] [Related]  

  • 39. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.
    Jameson SS; Rymaszewska M; Hui AC; James P; Serrano-Pedraza I; Muller SD
    J Bone Joint Surg Am; 2012 Sep; 94(17):1554-8. PubMed ID: 22832942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring of low molecular weight heparin in pregnancy.
    Shiach CR
    Hematology; 2003 Feb; 8(1):47-52. PubMed ID: 12623427
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.